Corporate naming is taking over. Welcome to Toronto, brought to you by Rogers
This satirizes our often ridiculous tendency to sell naming rights. But in a fragmented narrative that jumps back and forth chronologically, it also serves as an intentional point of confusion. As a reader, you have to work out and keep track of which years come in which order.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Toronto home prices could hit $1.8M, Vancouver $2.8M by 2032 without major supply boost: Report
Median home prices in Toronto could climb to $1.8 million and Vancouver's to $2.8 million by 2032 if the rate of new housing supply is not increased significantly, new research from Concordia University and private equity firm Equiton has found. The research, led by Erkan Yönder, an associate professor at Concordia's John Molson School of Business, uses a neural network-based AI model to find patterns among mountains of data. It quantifies how much more housing Canada's biggest cities will need in order to rein in prices — and offers granular projections on how approval delays or material costs can directly affect how much housing gets built. 'We see that supply should be multiplied, like, multiple times, not increasing 10 per cent, 20 per cent,' Yönder told Yahoo Finance Canada in an interview. 'They don't help enough.' Canada's housing supply problem is no secret and has long been at the forefront of policy conversations. Prime Minister Mark Carney's election platform included a promise to double the rate of housing construction over the next 10 years. The Concordia research shows that under Statistics Canada's baseline projections for population growth, doubling the rate of new completions would have strikingly different outcomes in different cities — but would likely stabilize price growth in Toronto and Vancouver. The report says Canada's current pace of building has completions at around 1.75 per cent of existing dwellings per year. The goal of doubling completions, the report says, 'while ambitious, is necessary to address affordability challenges, which will remain a generational issue for Canadians.' Toronto's median home price would climb from $1.4 million in 2024 to $1.8 million (in today's dollars) in 2032 under the current pace of housing completions, the report says — but it would slow to $1.6 million if completions doubled. In Vancouver, the report says government policy slowing immigration should lead to 'a modest dip' in the median price this year, but the current housing pace would see that price rise from $2.5 million to $2.8 million in 2032. A 50 per cent increase in completions would do little to slow the trend, the report says — only a doubling of completions would flatten prices. The diversity of Canada's housing markets also stands out in the research. While doubling supply could put the brakes on price growth in Toronto and Vancouver, the model projects a different outcome for Montreal. 'Even if you increase much, much more in Montreal, you cannot stop the price increases,' said Yönder. He explains that Montreal is on the 'wrong side' of an inverted supply curve, where intense demand overwhelms new inventory. This is fuelled by a construction pace of just 1.19 per cent of its housing stock, nearly half of Vancouver's (2.32 per cent). Because prices are still far lower than in other major cities, he adds, there is simply 'more room … for prices to go up.' Tariff policies cannot be considered without thinking about the housing supply. This is something to take very Yönder, associate professor at Concordia's John Molson School of Business Calgary, by contrast, is more responsive to shifts in immigration and population than to changes in supply. The model sees prices dropping in the near term from an immigration-driven peak of $740,000 in 2024, and remaining below that peak regardless of the pace of construction. The research quantifies the impact of reducing red tape and approval timelines. Improving a municipality's score by 10 per cent on the Regulation Index (a Canada Mortgage and Housing Corporation and Statistics Canada metric for zoning rules and assessments) would result in 10 per cent more homes being built, the research finds. A 10 per cent reduction in approval times would give a three per cent boost to supply. Yönder notes that making these adjustments has no expense. "If you improve the regulation process, decrease the delays, we can increase supply at no cost to the government,' he said. On the flip side, the research says that a 10 per cent increase in input costs can reduce housing completions by 25 per cent to 35 per cent, with apartment constructions most affected. Yönder notes that this connects Canada's housing goals directly to global trade and tariff policies. "The tariff policies cannot be considered without thinking about the housing supply," Yönder warned. "This is something to take very seriously." The professor acknowledges that while regulatory burdens aren't a new topic, this research 'is the first study which quantifies the impacts'. Understanding these levers is critical, he suggests, because the scale of the overall challenge is so immense. When asked if doubling housing completions is actually possible in a city like Vancouver, his answer was blunt. 'No,' he said. 'It's not possible... it's very costly. It's very difficult'. The value of the research, Yönder says, is in providing a clearer forecast that can yield better planning. "In the end, we can make better decisions by projecting better.' John MacFarlane is a senior reporter at Yahoo Finance Canada. Follow him on X @jmacf. Download the Yahoo Finance app, available for Apple and Android. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions
Launch supported by strong assay performance in first milestone readout of the landmark EXPAND clinical trial AUSTIN, Texas, August 07, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test (NIPT) for inherited conditions. When a pregnant patient is identified as a carrier of a recessive single-gene condition, medical guidelines recommend partner testing in order to determine the risk for the baby to be affected by the condition1; however, in some cases the biological father is unavailable for testing. The Fetal Focus test was designed to address this unmet need. Now if a pregnant patient tests positive with Natera's Horizon™ carrier screen for one of the five most commonly tested genes, and if the father is unavailable for testing, Fetal Focus can screen the fetus directly for that gene by simply analyzing a sample of the mother's blood. Fetal Focus is validated for the analysis of five genes: CFTR (cystic fibrosis), SMN1 (spinal muscular atrophy), HBA1 and HBA2 (alpha-thalassemia), and HBB (beta-hemoglobinopathies, including sickle cell disease). The launch is supported by data from EXPAND, a large, prospective, blinded clinical trial. The study, which was initiated in 2023, has enrolled approximately 1,300 participants to date, reflecting a diverse, multi-ethnic population from leading academic medical centers and maternal fetal medicine clinics. EXPAND is designed to be the defining clinical trial in the category, with all outcomes, including both positive and negative results, confirmed by genetic truth using prenatal or postnatal diagnostic testing. In its first milestone readout (n=101) from EXPAND, the Fetal Focus test demonstrated 91% sensitivity and successfully identified 5/5 fetuses affected by homozygous variants.2,3 Homozygous cases, where the fetus inherits the same condition-causing variant from both parents, are especially challenging to detect. Fetal Focus uses Natera's proprietary LinkedSNP™ technology to improve detection of these cases across diverse populations. "Having access to a noninvasive option like Fetal Focus can provide critical information to support decision-making during pregnancy, especially in situations where partner testing isn't possible," said John Williams, M.D., chief principal investigator for EXPAND and director of reproductive genetics at Cedars-Sinai. "Fetal Focus adds another important offering within our comprehensive reproductive health portfolio – furthering our commitment to launching products that address clinical gaps in care and are supported by rigorous clinical validation," said Sheetal Parmar, M.S., CGC, senior vice president of medical affairs for women's health at Natera. "The EXPAND study has been underway for several years, and we're pleased to release this first milestone readout." References ACOG Committee Opinion #690, Mar 2017. Internal data on file. In EXPAND, the study participants and investigators are blinded to the Fetal Focus™ test results. EXpanding Prenatal Cell Free DNA Screening Across MoNogenic Disorders (EXPAND). Accessed July 2025. About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and View source version on Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@ Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@ Sign in to access your portfolio
Yahoo
13 minutes ago
- Yahoo
New York Giants may have dodged a bullet by failing to acquire Matthew Stafford
New York Giants general manager Joe Schoen was given a directive by co-owner John Mara after the team finished the 2024 season with a 3-14 record. "The number one issue for us going into this offseason is to find our quarterback of the future," Mara said on January 6 after announcing that he was retaining Schoen and head coach Brian Daboll. "Whether that be via the draft or acquiring a veteran, it's going to be up to them to decide, ultimately." Schoen went to work and decided to head the rest of the league off at the pass. He would not wait for free agency or the draft to find his man. He zeroed in on Matthew Stafford, who, rumor had it, was being made available in a trade by the Los Angeles Rams. The situation resolved itself when Stafford decided to sign an extension with the Rams, sending the Giants back to the drawing board. The rest is well-known. Schoen rebounded by signing Russell Wilson and Jameis Winston in free agency and followed it up with a bold draft day trade that landed them prized prospect Jaxson Dart. As it turns out, the football gods were with the Giants in this situation. Stafford has a disc issue in his back that has sidelined him this summer. Schoen dodged a bullet for sure. The deal for Stafford was practically all but done before he decided to stay with the Rams. From Sports Illustrated: While they missed out on Stafford, it wasn't for lack of trying. According to NFL Network host Rich Eisen, the Giants not only matched the Rams' trade demands for Stafford, they also offered him a more lucrative contract than the deal he signed with Los Angeles. Despite that, Stafford chose to return to the Rams. "I heard the Giants and Raiders' interest in Matthew Stafford was quite real, and it was hairy at certain junctures last week. And I heard the Giants hit the number... and they hit the trade comp, too. They were in," said Eisen on The Rich Eisen Show. "The Giants even hired [Stafford's] brother in law, Chad Hall, on the coaching staff. And so, they really made a run." The Giants have clearly not looked back. Wilson has injected new life into the Giants' huddle, and Winston and Dart have added flavor and enthusiasm for the offense's future. This article originally appeared on Giants Wire: Giants may have dodged a bullet by failing to acquire Matthew Stafford
